Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5  by Roberts, Charles W.M et al.
A R T I C L E
Highly penetrant, rapid tumorigenesis through conditional
inversion of the tumor suppressor gene Snf5
Charles W.M. Roberts,1 Monique M. Leroux,1 Mark D. Fleming,2 and Stuart H. Orkin1,3
1Division of Hematology-Oncology, Dana-Farber Cancer Institute and Children’s Hospital, Department of Pediatrics, Harvard
Medical School and Howard Hughes Medical Institute, Boston, Massachusetts 02115
2 Department of Pathology, Children’s Hospital and Harvard Medical School, Boston, Massachusetts 02115
3 Correspondence: stuart_orkin@dfci.harvard.edu
Summary
Recent data suggest the SWI/SNF chromatin remodeling complex may also act as a tumor suppressor. Utilizing a reversibly
inactivating conditional allele, we demonstrate that loss of Snf5/Ini1/Baf47/SmarcB1, a core subunit of SWI/SNF, results
in highly penetrant cancer predisposition with 100% of mice developing mature CD8 T cell lymphoma or rare rhabdoid
tumors with a median onset of only 11 weeks. Notably, while loss of Snf5 predisposes to aggressive cancers, it is also
required for survival of virtually all nonmalignant cells in vivo. Reversible gene targeting demonstrates a critical and specific
role for Snf5 in tumor suppression, provides a novel system in which to explore the genetic pathways involved in tumor
suppression by Swi/Snf, and should be of wide use in evaluating other essential tumor suppressor genes.
Introduction Strober et al., 1996; Trouche et al., 1997; Zhang et al., 2000).
Subsequently, association of SWI/SNF with BRCA1 in a bio-
chemical complex was reported (Bochar et al., 2000). Specific,Tightly compacted chromatin provides an organizational struc-
ture for DNA but constitutes a significant barrier to gene expres- inactivating mutations in SNF5 were identified in the majority of
cases of malignant rhabdoid tumor, a rare but highly aggressivesion. Nucleosomal structures impede active transcription and
several chromatin remodeling complexes serve to modulate cancer of early childhood, and constituted the first genetic evi-
dence linking SWI/SNF to tumor suppression (Biegel et al., 1999;expression of genes by regulating local chromatin structure.
These remodeling complexes can be grouped into two broad Sevenet et al., 1999; Versteege et al., 1998). Inactivating muta-
tions in BRG1 have also been identified in several human tumorclasses—those that covalently modify histones with acetyl,
methyl, or phosphoryl groups and those that utilize the energy cell lines (Wong et al., 2000). Attempts to confirm the signifi-
cance of these findings in murine models have met with variableof ATP hydrolysis to mobilize nucleosomes. SWI/SNF, a 2 MDa
complex made up of 8 to 11 polypeptides, is the most intensively success. Mice deficient in either Brg1 or Snf5 die early in embry-
onic development and thus only haploinsufficient mice can bestudied of the latter class. Though originally identified in yeast,
the complex is present in all eukaryotes and highly evolutionarily assessed for cancer occurrence (Bultman et al., 2000; Guidi et
al., 2001; Klochendler-Yeivin et al., 2000; Roberts et al., 2000).conserved. In mammals several variants of SWI/SNF exist, each
containing one of two mutually exclusive ATPase subunits, Brg1 haploinsufficient mice display a mild tumor-prone pheno-
type with 3/20 mice developing glandular tumors, none of whichBRG1 or BRM. The complexes further differ in subunit composi-
tion but all contain the same active core that, in addition to exhibited loss of heterozygosity for Brg1. Snf5 haploinsufficient
mice are prone to developing tumors characterized by rhabdoidSNF5, consists of BAF155, BAF170, and either BRG1 or BRM.
(Phelan et al., 1999). cells and bear remarkable resemblance to human malignant
rhabdoid tumors. Like Brg1, Brm is present in only a subset ofWhile it has been known for a decade that SWI/SNF regu-
lates transcription through chromatin remodeling, it is only re- SWI/SNF complexes. Brm-deficient mice are viable and heavier
than normal, but do not appear tumor prone (Reyes et al., 1998).cently that several observations have indicated a potential link
between SWI/SNF and tumor suppression. BRG1 and BRM Of Swi/Snf genes inactivated in mice to date, only Snf5 is a
core member present in all Swi/Snf complexes. However, earlybind to the tumor suppressor Rb and are required for Rb-medi-
ated cell cycle arrest (Dunaief et al., 1994; Strobeck et al., 2000; embryonic lethality in Snf5-deficient animals precludes evalua-
S I G N I F I C A N C E
Chromatin remodeling complexes are essential for appropriate transcriptional regulation of large numbers of genes. Snf5 is a core
subunit of the SWI/SNF chromatin remodeling complex and is one of only a few subunits present in all variants of the complex.
Recent data suggest that SWI/SNF may serve an important tumor suppressor role for a variety of cancers. However, the data have
often been indirect in nature and mouse knockout experiments have been hampered by lethality. While haploinsufficient models
have provided support to this association, long latency and low penetrance have hampered further analysis. Utilizing a novel
conditional targeting approach that should be useful in the characterization of other tumor suppressor genes, we demonstrate that
controlled inactivation of Snf5 in vivo results in extremely rapid development of aggressive cancers with high penetrance.
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mediated deletion of the floxed allele by the Gata1-Cre trans-
gene resulted in lethality of Snf5floxed/ embryos (data not shown).
We next considered the use of various lines of transgenic
Cre-expressing mice that would be useful in the evaluation of
Snf5 function. We ultimately chose Mx-Cre mice for two rea-
sons. First, expression of Cre from the Mx promoter is inducible
and could therefore circumvent embryonic lethality caused by
loss of Snf5. The Mx promoter is activated by injection of inter-
feron or, alternatively, by administration of the interferon-inducer
Figure 1. Snf5 conditional targeting construct synthetic double-stranded RNA (polyI/polyC), (Kuhn et al.,
The conditionally targeted allele with the neomycin resistance cassette 1995). Second, following induction of Mx-Cre mice, Cre-medi-
removed is shown on top and the allele that results following Cre expression ated excision occurs to some degree within all tissues with the
is shown below.
exception of brain. Widespread excision was essential because
the cell of origin of malignant rhabdoid tumor is unknown. We
therefore bred Mx-Cre mice onto the Snf5floxed background.
Following polyI/polyC administration, high levels of Cre-tion of tumor development in its absence. Conditional targeting
mediated excision were achieved in bone marrow, liver, thymus,utilizing the loxP-Cre system provides an alternate strategy as
and spleen and moderate levels in all other tissues tested includ-a target gene flanked by loxP sites may be inactivated in vivo
ing muscle, heart, lung, GI tract, kidney, uterus, ovaries, andin liveborn mice by expression of the bacteriophage Cre recom-
testes. The only tissue that lacked excision was brain. Whereasbinase (Lewandoski, 2001; Sauer and Henderson, 1989).
polyI/polyC treatment of 10 Snf5floxed//Mx-Cre mice had no ef-In order to circumvent embryonic lethality and evaluate the
fect on survival, treatment of Snf5floxed//Mx-Cre mice resultedeffect of biallelic loss of Snf5, we generated strains of mice with
in dramatic findings. Between 1 and 3 weeks after injection,two different conditional mutations at the Snf5 locus—one a
90% of Snf5floxed//Mx-Cre mice died; the remainder died overconditionally targeted Snf5 allele and the other a reversibly inac-
the ensuing 4 weeks. This occurred whether mice were injectedtivating allele. These mice were bred to transgenic strains that
as neonates or adults. By 1–2 weeks following polyI/polyC ad-express Cre recombinase either in the very early embryo or
ministration, mice appeared ill and were profoundly pancytope-
following induction with interferon. Using this approach, we
nic. Mice often displayed extensive bruising of the skin and
report a powerful system for evaluating conditional oncogenesis
intestinal hemorrhage (Figures 2A and 2B). Histological analysis
mediated by Snf5 loss. This approach should also prove useful
of bone marrow revealed an extreme deficiency of hematopoi-
for evaluating other essential tumor suppressor genes. etic cells (Figure 2C). Presumably bone marrow aplasia led to
low platelet counts, bleeding, anemia, oxygen deprivation, and
Results death. Several mice developed only transient mild/moderate
pancytopenia. Despite daily monitoring and a healthy appear-
Inactivation of Snf5 in conditional Snf5floxed/ mice leads ance, these latter mice succumbed to sudden death, the etiol-
to rapid demise ogy of which is unclear. Of note, a single mouse developed a
Previously we generated a targeted Snf5 null allele (Snf5) (Rob- lymphoma 12 days after injection. These findings demonstrate
erts et al., 2000). Snf5/ mice are early embryonic lethal. that continued Snf5 is required for survival of both neonatal and
Haploinsufficient Snf5/ mice are predisposed to rhabdoid tu- mature mice and is necessary for maintenance of hematopoietic
mors that bear a striking histologic resemblance to human ma- cells within the bone marrow. Rapid demise due to widespread
lignant rhabdoid tumors. Further follow-up of a cohort of Snf5/ inactivation of Snf5 in Snf5floxed/ mice, however, precludes their
mice has revealed an overall tumor incidence of 12%. In total, use as a tumor model.
28 mice have developed tumors with a median onset of just
over one year. All but one of the tumors was of the rhabdoid Generation of a reversible, inverting conditional
type. While this establishes a firm link between Snf5 and tumor Snf5 allele (Snf5inv)
suppression, the low penetrance and high median age have We reasoned that decreasing the penetrance of Snf5 loss in
precluded the use of Snf5/ mice as a practical tumor model bone marrow and other tissues might circumvent lethality be-
with which to study the involvement of Snf5 in critical cellular cause unaffected progenitor cells would proliferate and com-
pathways. pensate for the death of affected cells. Moreover, even partial
To recapitulate the Snf5 null mutation utilizing a conditional penetrance would still be expected to generate many Snf5 null
allele, we generated a targeting construct in which exon 1 is cells, which might be highly tumor predisposed. To establish
flanked by loxP sites (floxed) (Figure 1). Thus, following exposure such an animal model, we modified the Snf5 locus so that it
to Cre recombinase, exon 1,which contains the initiator ATG, could be reversibly inactivated via Cre-mediated gene inversion,
is deleted. Following appropriate targeting in ES cells, condition- an approach first used by Lam and Rajewsky in the context of
ally targeted Snf5floxed mice were generated. B-lymphoid cell function (Lam and Rajewsky, 1998)—here, we
To confirm that inactivation of the Snf5floxed allele recreates apply this approach to cancer modeling.
a Snf5 allele, we bred mice carrying the conditional allele to In construction of traditional conditional alleles with the loxP-
mice carrying both the Snf5 allele (Snf5/) and the Gata1-Cre Cre recombination system, 34 base pair loxP sites are placed
transgene (Gata1-Cre). Gata1-Cre is expressed very early in in the same directional orientation flanking a target DNA region.
embryonic development and results in ubiquitous deletion of Upon expression of Cre recombinase, crossing-over results in
the excision of DNA between the loxP sites (Figure 3A). In con-floxed target sequences (Mao et al., 1999). As anticipated, Cre-
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administration of polyI/polyC, only 50% of the alleles would end
up in the inverted orientation if no biological selection were
imposed.
We generated the reversible inverting conditional allele of
Snf5, designated Snf5inv with the targeting vector shown (Figure
3C). We predicted that inversion of exon 1 would inactivate the
gene given that mutations within exon 1 predispose to cancer
in humans and because no alternative initiation sites are present
downstream of the initiator ATG. Snf5inv/inv mice appear normal
in the absence of Cre expression (data not shown).
To validate the properties of the Snf5inv allele, we first exam-
ined the consequences of expressing Cre recombinase within
the germline (or very early embryo) of Snf5inv/ mice through use
of the Gata1-Cre transgene. As was the case with Snf5floxed//
Gata1-Cre mice, Snf5inv//Gata1-Cre mice were embryonic lethal
suggesting that loss of Snf5 in a substantial proportion (or 50%)
of cells during embryonic development is incompatible with
survival. To test the Snf5inv allele further, we then analyzed polyI/
polyC-treated Snf5inv/ mice carrying the Mx-Cre transgene. We
predicted that there would be no selective disadvantage to
inversion of Snf5 in this genetic background. Administration of
polyI/polyC was tolerated without any adverse effects. DNA
analysis validated the properties of the Snf5inv allele. In organs
where induction of the Mx promoter is highly efficient such as
bone marrow, 50% of DNA derived from the Snf5inv allele was
in the germline (active) orientation and 50% in the inverted
(inactive) orientation (Figure 3D). In those tissues in which the
Mx-Cre transgene is less well expressed, a smaller fraction of
the Snf5inv derived DNA was in the inverted orientation. Recom-
bination was detected within all tissues with the exception of
brain where the Mx-Cre transgene is not expressed.
Highly penetrant, rapid tumor formation following
Cre-mediated inversion in Snf5inv/ mice
The effect of polyI/polyC-activated Cre expression on the short-
term survival of Snf5inv//Mx-Cre mice was strikingly different
from that observed with Snf5floxed//Mx-Cre mice. Rather than
succumbing within the three weeks following polyI/polyC ad-
Figure 2. Inactivation of Snf5 with Mx-Cre leads to hemorrhage and pancy- ministration, Snf5inv//Mx-Cre mice initially appeared normal.
topenia However, beginning at 4 weeks following injection, Snf5inv//
A: Subcutaneous hemorrhage is present over the right thorax and abdomen Mx-Cre mice developed cancer. The susceptibility to tumor
of a Mx Snf5Cond/ pup that was injected with polyI/polyC one week earlier. formation was dramatic: 100% of the mice developed tumors
B: Abdominal organs of a Mx Snf5Cond/ mouse injected with polyI/polyC
with a median onset of only 11 weeks post-polyI/polyC (Figureeight days earlier demonstrating extensive intestinal hemorrhage. The color
4). Mice displayed an enlarged lymph node or dramatically en-of the intestine (I) is normally close to that of the stomach (S) or bladder
(B) but in this case is dark red due to bleeding. Liver (L). larged spleens and livers (Figures 5A–5C). This was often ac-
C: A section through the femur of an adult Mx Snf5Cond/ mouse that was companied by a mild progressive decrease in blood counts, an
injected with polyI/polyC 16 days earlier. The bone marrow contains only increase in circulating eosinophils, and occasionally by circulat-mature red blood cells and there is virtually no hematopoietic activity.
ing tumor cells (Figure 5D). Histologic analysis revealed efface-Reference bar  50 m.
ment of normal architecture in involved lymph nodes and spleen
(Figure 5E) and peri-portal involvement frequently in liver (Figure
5F). Bone marrow was typically devoid of malignant cells al-
though it often contained moderately increased numbers oftrast, Cre-mediated inversion takes place when the flanking loxP
eosinophils. At high-magnification the tumors revealed a pleo-sites are placed in opposing orientation (Figure 3B). This is a
morphic mixture of small to intermediate sized cells includingreversible event since both loxP sites are recreated on the same
a predominant population of intermediate sized cells with irregu-strand of DNA following inversion. Previously, Lam and Rajew-
lar to cleaved nuclei, vesicular chromatin, and variably distinctsky (Lam and Rajewsky, 1998) demonstrated that Cre-mediated
nucleoli (Figures 5G and 5H). Mitotic figures were frequent. Theinversion occurs with high efficiency. We reasoned that following
histologic appearance of the tumor cells was highly suggestivetransient expression of the Cre protein within cells a steady
state would be rapidly reached between alleles that were in the of malignant lymphocytes.
Tumors were characterized further by immunohistochemis-germline orientation and those in the inverted orientation. Thus,
in any given tissue, even if 100% of cells expressed Cre following try. Findings were consistent in eight tumors that were analyzed
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Figure 3. An inverting conditional allele allows for reversible inactivation and results in partial penetrance of Snf5 loss
A: Diagram of a conditionally targeted allele containing loxP sites in identical orientations. Following expression of Cre, DNA between the LoxP sites is
removed and the loxP sites are recreated on separate DNA molecules making the reaction essentially irreversible.
B: Diagram demonstrating the effect of placing loxP sites in opposing orientations. Following expression of Cre, DNA between the loxP sites is inverted.
Since both loxP sites remain on the same DNA strand, the reaction is entirely reversible.
C: Inverting conditional Snf5 construct. The construct was made by reversing the orientation of the floxed neomycin resistance cassette within intron 1 and
then transfecting ES clones to remove the neomycin resistance cassette.
D: Southern blot of DNA from the organs of a Mx Snf5Inv/ mouse one month after injection with polyI/polyC. Lane 1 contains tail DNA obtained from the
mouse prior to injection with polyI/polyC and demonstrates presence of the wild-type and inverting conditional allele in the active orientation only. Lane
2 contains DNA from the tail of the mouse obtained following injection with polyI/polyC. The Mx promoter is weakly expressed in tissues of the tail but there
is now a faint band corresponding to the inverting allele in the inactive orientation while the majority of the inverting allele remains in the active orientation.
In contrast, Mx-Cre is highly expressed in thymus, bone marrow, spleen, and liver, and close to 50% of the inverting allele is located in the inactive orientation
within these organs—demonstrating that despite close to 100% expression of Cre, only 50% of the inverting allele is in the inactive orientation.
(Figure 6). All tumors were positive for the T cell markers Thy1.2, Inactivation of Snf5 in T cell lymphomas
of polyI/polyC-treated Snf5inv/ miceCD3, and CD8 and negative for CD4, immature T cell (TdT), B
cell (B220), and myeloid (Mac-1 and Gr-1) markers. Tumors The orientation of the Snf5inv allele was determined in various
tissues and tumors in multiple Snf5inv//Mx-Cre mice by South-were highly vascular as assessed by CD31 (PECAM) staining.
These findings define the tumors as mature CD8 T cell lympho- ern blot analysis (Figure 7B). In all tissues other than tumor,
virtually all Snf5inv-derived DNA was in the normal (active) orien-mas (Morse et al., 2002), a tumor type not seen in Snf5 haploin-
sufficient mice. tation. In contrast, in lymphoma DNA the majority of Snf5inv-
derived DNA was in the inverted (inactive) orientation. Since theTo examine potential clonality of these mature T cell lympho-
mas, we performed Southern analysis of the  T cell receptor inverting event is detectable in most tissues only when the Snf5inv
allele is paired with a wild-type allele but not when it is pairedlocus. As shown in Figure 7A, we observed monoclonal re-
arrangements in each tumor with one tumor containing two with a knockout allele (compare Figure 3D to Figure 7B), we
infer that loss of Snf5 is lethal to virtually all cells and yet alsodiscrete rearranged bands. In total, 28 Snf5inv/ mice carrying
Mx-Cre have been treated with polyI/polyC. Twenty-three devel- predisposes to malignant transformation. The small amount of
Snf5inv allele DNA in the functional orientation within the tumoroped cancer within 24 weeks following injection and another
five were found dead with advanced autolysis precluding evalu- very likely reflects the presence of nonmalignant cells, such as
endothelial and inflammatory cells, which are abundant in theseation of the cause of death. Of the 23 evaluable mice, 20 devel-
oped lymphomas and 3 developed rhabdoid tumors. tumors.
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Figure 4. Survival of Snf5 targeted mice
Snf5/ mice are predisposed to develop rhab-
doid tumors. Overall, there is a 12%–15% pene-
trance with a median onset of 12 months. Mx
Snf5Cond/ mice (designated Stc/) die rapidly of
bone marrow and organ failure following injec-
tion with polyI/polyC. 90% of the mice die within
3 weeks and the remainder over the next four
weeks. Mx Snf5Inv/ mice succumb to cancer
with a penetrance of 100% and median latency
of 11 weeks after injection with polyI/polyC.
Effects of Snf5 loss upon lymphoid subpopulations 24 hr following a single dose of polyI/polyC there was increased
The finding of exclusively CD8 mature lymphomas in Snf5inv// apoptosis in Snf5floxed//Mx-Cre mice when compared either to
Mx-Cre mice is particularly interesting since mice normally have uninduced mice of the same genotype or to induced Snf5floxed//
a 4:1 predominance of CD4:CD8 mature T cells. It was re- Mx-Cre control mice at the same time points. The increased
cently reported that two other subunits of Swi/Snf, Brg1 and apoptosis was readily detected by flow cytometric analysis of
Baf57, are involved in suppression of CD4 expression and acti- anexin-V staining of splenocytes (Figures 8C and 8D), by TUNEL
vation of CD8 expression during thymocyte development (Chi staining in liver and spleen (Figures 8E–8H) and by histologcial
et al., 2002). We thus sought to evaluate whether Snf5 loss had analysis (Figures 8I and 8J).
differential effects upon lymphocyte subpopulations in spleen
and thymus. Splenocytes and thymocytes were evaluated at Discussion
12, 18, 24, 36, 48, 96, and 216 hr following induction with polyI/
polyC. There was a progressive loss of hematopoietic cells Highly penetrant, short latency tumor formation
within both tissues as well as in bone marrow. Lymphocyte upon inactivation of Snf5
subsets within the spleen were lost at equal rates following The data presented here demonstrate that Snf5, a core member
inactivation of Snf5. There was no difference in the CD4:CD8 of the SWI/SNF chromatin remodeling complex, is vital for tumor
ratio or in the T cell:B cell ratio in spleen following induction suppression in vivo and is also required for the survival of most
(Figures 8A and 8B). Further, we examined V rearrangements normal cells. The rapidity with which tumors develop following
in splenic T cells and found no change in the relative prevalence
inducible inactivation of Snf5 is unprecedented. 100% percent
of individual V segments following induction (not shown). Simi- of mice develop tumors with a median latency of 11 weeks. Inlarly, inactivation of Snf5 led to an equal loss of thymocyte
comparison, the time to tumor development with other tumorsubsets. No significant differences were detected in
suppressors is significantly longer. p53-deficient mice developCD4CD8, CD4CD8, or CD4CD8 thymocyte subsets ei-
tumors at a median age of 20 weeks (not including the 3 weeksther in total thymus or in the TCR lo/ fraction (not shown).
of embryonic development without p53), p19/Arf knockout miceThese data suggest that the development of exclusively CD8
at 38 weeks, p16/Ink4a mice at 60 weeks, and loss of p21/lymphomas is not due to differential lethality within lymphocyte
Cip1/Waf1 does not lead to a detectable increase in tumorsubsets following Snf5 inactivation.
formation in mice (Brugarolas et al., 1995; Donehower et al.,
1992; Serrano et al., 1996; Sharpless et al., 2001). InactivationCell death following loss of Snf5
of the tumor suppressors Rb, Apc, Pten, Vhl, or Nf1 each leadsSince inactivation of Snf5 led to the loss of large numbers of
to embryonic lethality (Bollag et al., 1996; Di Cristofano et al.,cells in addition to oncogenic transformation, we sought to
2001; Gnarra et al., 1997; Largaespada et al., 1996; Lee et al.,determine whether apoptosis occurred following induction.
1992; Su et al., 1992). Haploinsufficiency for Rb leads to tumorSnf5floxed//Mx-Cre mice were induced with polyI/polyC and tis-
formation with a median latency of 45 weeks while combinedsues harvested at 12, 18, 24, 36, 48, 96, and 216 hr post-
p53 deficiency and Rb haploinsufficiency yields tumors at 17induction. We focused our analysis upon liver and spleen be-
weeks (Williams et al., 1994). Thus, the aggressive cancer-pronecause these organs are the most common sites of lymphoma
phenotype that occurs following reversible inactivation of theoccurrence and have high levels of Cre activity. No increase in
apoptosis was evident at 12 hr post-induction. However, at 18 to Snf5 gene is striking when compared to other tumor suppressor
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progressive, animals may die of lymphoma prior to the appear-
ance of more slowly growing solid tumors. For instance, this
may explain why the overall incidence of rhabdoid tumors in
the inverting system is the same as in the haploinsufficient mice
(10%–15%) despite a significantly earlier onset of 4.6 months
in the inverting mice instead of just over 12 months in the
haploinsufficient mice. Second, the high proliferative rate of
hematopoietic cells combined with the high activity of the Mx-
Cre transgene in this tissue may select for the occurrence of
lymphomas although this would not explain the specific predi-
lection for mature CD8 T cell lymphomas per se. Third, recent
data demonstrate roles for the Swi/Snf subunits Baf57 and Brg1
in activation of CD4 expression and repression of CD8 expres-
sion (Chi et al., 2002). If Snf5 also plays a role in controlling the
development of T cells then loss of Snf5 may impair T cell
development and predispose to malignant transformation of
maturing CD8 T cells. However, using flow cytometric analysis
we were unable to detect differential effects upon T cell subsets
following inactivation of Snf5. It must be noted, though, that
induction of Mx-Cre relies upon increased levels of interferon,
and it is thus possible that the presence of interferon obscurred
subtle thymic developmental effects following Snf5 inactivation.
Tumor suppression by other Swi/Snf subunits
It is not yet clear whether tumor suppression is specific to Snf5
or is a more general property of the Swi/Snf complex. Several
lines of evidence suggest that the tumor suppressor activity of
Snf5 is related to the role of the Swi/Snf complex in chromatin
remodeling. First, other chromatin remodeling complexes, par-
ticularly histone acetylase (HAT) and deacetylase (HDAC) fac-
tors, are involved in recurrent chromosomal translocations and
Figure 5. Lymphomas in Mx Snf5Inv/ mice
have been implicated in oncogenesis. Second, Brg1 and Brm,
A: Mouse demonstrating markedly enlarged lymph node secondary to lym- mutually exclusive catalytic ATPase-containing subunits of Swi/
phoma.
Snf, each bind to Rb and are required for Rb-mediated cellB: Spleen from mouse with lymphoma (top) compared to spleen from nor-
cycle arrest. (Dunaief et al., 1994; Trouche et al., 1997). Third,mal littermate (bottom).
C: Liver from mouse with lymphoma (top) compared to litter from normal the Swi/Snf complex is also part of the Brca1 biochemical com-
littermate (bottom). plex and Brg1 directly binds to Brca1 (Bochar et al., 2000).
D: Peripheral blood smear demonstrating the presence of three malignant
Fourth, mutations in BRG1 have been detected in several humanwhite blood cells. Reference bar  10 m.
tumor cell lines and, while inactivation of Brg1 results in embry-E: Section from involved spleen demonstrating widespread necrosis and an
island of malignant lymphocytes. Reference bars  100 m. onic lethality in mice, 3 of 30 Brg1 haploinsufficient mice devel-
F: Section through involved liver demonstrating peri-portal infiltration of lym- oped glandular tumors (Bultman et al., 2000). Most recently,
phoma. Reference bars  100 m. HLTF, a member of the Swi/Snf family, was demonstrated toG and H: Sections through two different lymphomas demonstrating uniform
be specifically silenced in human colon cancers (Moinova ethistologic appearance of the lymphomas. The lymphomas consist of a
al., 2002) and BAF180 was found to have specific nonsensepredominant population of intermediate sized cells with irregular nuclei,
vesicular chromatin, and variably distinct nucleoli. Mitotic figures are fre- mutations in two of 40 primary breast cancers (Ramon Parsons,
quent. Reference bar  10 m. personal communication). Thus, there is accumulating evidence
that the entire Swi/Snf complex is involved in growth regulation
and may have a widespread role in tumor suppression. Since
Snf5 is an invariant subunit in all Swi/Snf complexes, furtherknockouts and indicates a critical role for Snf5 in preventing
elucidation of its function and interacting pathways is likely tocancer.
generate insight into this newly appreciated mechanism of tu-The limited spectrum of tumors arising after Snf5 inactivation
mor suppression.is particularly interesting. While disruption of tumor suppressors
While the above data support a generalized role for the Swi/such as p53, p19/Arf, and Pten predisposes to a wide variety
Snf complex in tumor suppression, the fact that distinct tumor-of cancers, inactivation of others leads to specific phenotypes.
prone phenotypes result following inactivation of different Swi/For example, haploinsufficiency for Rb, a gene known to be
Snf subunits suggests that the complex does not solely act incritical in tumor suppression in humans, yields exclusively pitu-
a single pathway. Rather, we speculate Swi/Snf may be involveditary adenocarcinomas in mice, an otherwise rare tumor (Hu et
in diverse growth control pathways and inactivation of individualal., 1994). Similarly, inactivation of Snf5 in our system gives rise
subunits leads to altered expression of only subsets of Swi/to two specific types of tumors. The basis for this specificity
Snf-regulated genes. Thus, loss of Brg1 promotes glandularremains unclear but several possibilities exist. First, since the
lymphomas occur early, have a high mitotic rate, and are rapidly tumors while inactivation of Snf5 leads to rhabdoid tumors and
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Figure 6. Loss of Snf5 gives rise to mature CD8 T cell lymphomas
Immunohistochemical staining was performed on eight lymphomas from Mx Snf5Inv/ mice that had been injected with polyI/polyC. Representative sections
are shown.
A: IgG2a negative control.
B: CD31 (PECAM) reveals a high degree of vascularity.
C: Mac-1 stains only scattered macrophage/monocyte cells within the tumor mass.
D: Gr-1 stains only occasional neutrophils within the tumor.
E: B220 identifies a few B cells within the tumor.
F: The vast majority of cells are positive for this T cell marker.
G: The vast majority of cells are also positive for this T cell marker, although it is slightly less intense than thy1.2.
H: All tumors were negative for CD4 with the exception of a very few cells.
I: All tumors were positive in the vast majority of cells for this marker.
lymphomas. Given the high penetrance and rapid lethality ptotic death. However, rare cells that harbor an additional pre-
disposing mutation such as in ras, bcl2, or bax undergocaused by lymphomas following conditional inactivation of Snf5,
it will be interesting to determine whether other, slower growing, increased proliferation/survival and are predisposed to malig-
nancy (Hoffman et al., 2002). Thus, loss of Snf5 may result intumors occur in the absence of Snf5 but never become manifest
due to early death of lymphoma-laden mice. Ultimately, identifi- establishment of an epigenetic state that leads to cell death
except in those rare cells that contain additional mutations andcation of interacting pathways and downstream targets of Snf5
as well as evaluation of cancer-prone phenotypes in mice defi- progress to cancer.
cient for other Swi/Snf subunits will be required in order to
identify specific roles for Snf5 and Swi/Snf in cancer. Snf5 and human cancer
The types of tumors that develop in the Snf5inv/ mice carrying
the Mx-Cre transgene closely resemble specific human tumors.Snf5 is required in nonmalignant cells
It is interesting that loss of Snf5 expression ultimately results The histologic appearance of the rhabdoid tumors is essentially
indistinguishable from human malignant rhabdoid tumors thatin the death of cells and yet also predisposes to malignant
transformation. This apparent paradox is not without precedent carry biallelic inactivating mutations in hSNF5. The clinical pre-
sentation and histologic appearance of mice with mature T cellin oncogenesis as illustrated by findings with c-myc. Overex-
pression of c-myc causes most primary cells to undergo apo- lymphoma/leukemia is highly reminiscent of human mature T
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Figure 7. Loss of Snf5 leads to monoclonal lymphomas and loss of nonmalignant cells
A: Southern blot of DNA obtained from tail and tumor samples of mice with lymphoma. The blot was hybridized with a probe to the V region of the T cell
receptor. The three thymus lanes demonstrate the germline band at the top and faint polyclonal smears throughout the lane. The tail samples contain
only the germline band and each has a distinct clonal band within the tumor sample. In the case of mice Mx74 and Mx145, tumor samples consisted of
pieces of involved spleen and liver. B: Southern blot of DNA isolated from the organs and lymphoma of a Mx Snf5Inv/ mouse that had been injected with
polyI/polyC. The tail DNA was harvested prior to injection and demonstrates the unrearranged bands. Of note, in the knockout allele (), exon 1 has been
replaced with a neomycin resistance cassette surrounded by loxP sites. Thus, in the presence of Cre, the neomycin cassette is removed leading to a
change in size on the Southern blot while the allele remains inactive due to continued absence of exon 1. Comparison of the KO(neo) band to the
KO(neo) band demonstrates that there has been virtually 100% excision within thymus and bone marrow, over 90% excision in spleen, liver, and tumor
samples, and 20%–40% excision in the remaining organs with the exception of brain where there is no excision. In contrast, despite high levels of Cre
expression, the vast majority of the inverting allele remains in the active orientation with the exception of the tumor sample where the majority is in the
inactive orientation.
cell leukemia/lymphoma in which patients typically present with geting strategies are required in order to evaluate the normal
isolated adenopathy or with markedly enlarged spleen and liver. function of these genes and generate useful cancer-prone ani-
Elevated eosinophil counts and infiltration of tumor masses with mal models. Conditional targeting typically makes use of site-
nonmalignant inflammatory cells are common in such patients. specific recombinases, either the Cre-loxP system derived from
Mature T cell lymphoma/leukemia is among the most aggressive bacteriophage P1 or the Flp-Frt system derived from Sacchara-
of human lymphoid neoplasms and is typically refractory to romyces cerevisiae (Lewandoski, 2001). In combination with
treatment with chemotherapy. Notably, the high frequency of transgenes that drive tissue-specific Cre/Flp expression, inacti-
mature T cell leukemia/lymphoma in the Snf5inv/ mice suggests vation of a gene of interest can be directed to a specific tissue.
a potential link to human cancer where 45% of cases of mature However, many tumor suppressor genes are essential for sur-
T cell prolymphocytic leukemia have loss of genetic material at
vival, and deletion of the gene within specific tissues/organschromosome 22q11, the location of SNF5 (Soulier et al., 2001).
may lead to death of the mouse via loss of organ function.We are currently investigating the status of Snf5 within these
The strategy we have used serves to counter this problem andhuman tumors.
provides several advantages. First, we have utilized an inducible
system so that embryonic lethality due to loss of essential geneAdvantages of reversible inverting conditional alleles
functions is minimized. Second, the approach leads to repro-for tumor modeling in mice
ducible mosaic partial penetrance within multiple tissues. Con-Given that many tumor suppressor genes are essential for sur-
vival of individual cells or the whole organism, conditional tar- sequently, significant numbers of cells lose expression of the
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targeted gene and become predisposed to malignant transfor-
mation, while at least half of cells retain expression and prevent
death of the animal due to organ failure.
The system we have developed should also prove ideal for
identifying interacting genetic pathways participating in tumor
suppression. The tumors that result from inactivation of Snf5
are highly penetrant and develop over a narrow time course.
Thus, examining the effects of other genetic mutations on tumor
formation in Snf5inv mice provides a robust system in which to
pursue how Snf5 loss contributes to oncogenesis, either through
established tumor suppressor pathways or through novel mech-
anisms.
Experimental Procedures
Generation of Snf5 conditionally targeted mice
An 8.8 kb region of homology beginning 4.1 kb 5 of exon 1 and continuing
to the BamHI site in intron 1 was used to generate the targeting constructs.
A neomycin resistance cassette flanked by loxP sites was blunt-end ligated
into the XcmI site 1.4 kb 3 of exon 1 and this was transformed into E. coli.
A clone with the loxP sites pointed in the 3 direction was selected. Polylinker
and loxP sites were inserted at the EcoRv site 0.8 kb upstream of exon 1
such that the loxP site pointed 3. An HSV-TK cassette was inserted at
the BamHI site at the 3 end of the homology region. This construct was
electroporated into CJ7 ES cells (strain 129) and clones were selected in
G418 and gancyclovir. Six of 114 clones had undergone homologous recom-
bination. Three of these six clones had incorporated the 5 loxP site and two
of these had good karyotypes. In order to remove the neomycin resistance
cassette and leave only the loxP sites behind, one of these clones (#108)
was electroporated with the pMC-Cre expression plasmid. Fourteen of 96
clones were now G418 sensitive and 4 of these 14 clones retained exon 1.
Two of these clones (#7 and #8) had good karyotypes and were injected
into blastocysts. Both gave rise to high percentage chimeric mice and both
led to germline transmission.
Generation of Snf5 inverting conditional mice
The inverting construct was generated identically to the conditional construct
described above with the exception that a bacterial clone containing the
loxP sites of the neomycin cassette pointing in the 5 direction was used.
This construct was electroporated into CJ7 ES cells and clones were selected
in G418 and gancyclovir. Twenty of 103 clones underwent homologous
recombination and ten of these retained the 5 loxP site. In order to prevent
transcriptional interference from the neomycin resistance gene, one of these
clones (#31) was transduced with the pMC-Cre expression plasmid and
subclones that had deleted the neomycin cassette but retained exon 1 of
Snf5 were identified. Thirty of 115 clones were now G418 sensitive and 5
of these retained exon 1. Two of these clones (#26 and #28) had good
karyotypes and were injected into blastocysts. Both gave rise to high-per-
Figure 8. Lymphocyte development and apoptosis following inactivation centage chimeric mice and both led to germline transmission.
of Snf5
A and B: Flow cytometry of CD4 and CD8 staining of splenocytes from Mx-Cre induction
Snf5floxed//Mx-Cre control mice (A) and Snf5floxed//Mx-Cre mice (B). The sam- Induction of Mx-Cre in vivo was accomplished via one of two regimens.
ples shown are from 216 hr post-induction. No differences were apparent Neonatal mice (day of life 3) were injected subcutaneously with 200 g of
at any of the times examined. polyI/polyC (# P-0913, Sigma Chemicals, St. Louis, MO) daily for 5 days.
C and D: Two-color staining of nonpermeabilized splenocytes with Anexin-V
Mature mice (four to eight weeks of age) were injected intraperitoneally with
and propidium iodide (PI) from Snf5floxed//Mx-Cre control mice (C) and
Snf5floxed//Mx-Cre mice (D) are shown at 24 hr post-induction. Viable cells
are Anexin-V negative and PI negative (lower left quadrant), necrotic cells
are positive for both markers (upper right quadrant) and apoptotic
cells are positive for Anexin-V but negative for PI (lower right quadrant). Note
the increase in apoptotic cells in the Snf5floxed//Mx-Cre mice compared to H: TUNEL reaction performed on a liver section from the same Snf5floxed/
the control mice. /Mx-Cre mouse in the first two panels. Note the increased apoptosis in
E: Negative control TUNEL reaction performed without TdT enzyme on liver comparison to the control mouse.
from a Snf5floxed//Mx-Cre mouse at 18 hr after induction. I: H&E stained spleen section from a Snf5floxed//Mx-Cre mouse at 96 hr post-
F: Positive control TUNEL reaction from the same mouse. The liver section induction. Arrows identify cells with the morphologic appearance of late
was treated with DnaseI prior to performing the TUNEL reaction in order to stage apoptosis while the arrowhead points to a tingible body macrophage
generate DNA strand breaks. that has engulfed several apoptotic cells.
G: TUNEL reaction performed on a liver section from a Snf5floxed//Mx-Cre J: Liver section from a Snf5floxed//Mx-Cre mouse. The arrow indicates a late
control mouse 18 hr after induction with polyI/polyC. stage apoptotic cell.
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Bollag, G., Clapp, D.W., Shih, S., Adler, F., Zhang, Y.Y., Thompson, P.,300 g of polyI/polyC every other day for five doses. There was no apparent
Lange, B.J., Freedman, M.H., McCormick, F., Jacks, T., and Shannon, K.toxicity associated with either of these regimens.
(1996). Loss of NF1 results in activation of the Ras signaling pathway and
leads to aberrant growth in haematopoietic cells. Nat. Genet. 12, 144–148.Immunohistochemistry
Immunohistochemistry was carried out utilizing commercially available stain- Brugarolas, J., Chandrasekaran, C., Gordon, J.I., Beach, D., Jacks, T., and
ing kit (ABC kit, #SC-2019, Santa Cruz Biotechnology, Santa Cruz, CA) and Hannon, G.J. (1995). Radiation-induced cell cycle arrest compromised by
antibodies (PharMingen, San Diego, CA) reactive to the following epitopes: p21 deficiency. Nature 377, 552–557.
B220 (#01121A), Gr-1 (#557445), Mac-1 (557394), IgG2a (553927), IgG1
Bultman, S., Gebuhr, T., Yee, D., La Mantia, C., Nicholson, J., Gilliam, A.,(553969), Thy-1.2 (553000), CD31 (557355), IgG2b (553986), CD3 (557306),
Randazzo, F., Metzger, D., Chambon, P., Crabtree, G., and Magnuson, T.CD4 (553043), CD8 (558733).
(2000). A Brg1 null mutation in the mouse reveals functional differences
among mammalian SWI/SNF complexes. Mol. Cell 6, 1287–1295.
Southern Analysis
Genotyping of mice was done by hybridizing a labeled 0.6 kb XcmI fragment Chi, T.H., Wan, M., Zhao, K., Taniuchi, I., Chen, L., Littman, D.R., and
Crabtree, G.R. (2002). Reciprocal regulation of CD4/CD8 expression by SWI/located 3 kb upstream of exon 1 to BamHI digested DNA. Deletion and
SNF-like BAF complexes. Nature 418, 195–199.inversion of the conditional alleles was performed using a labeled 0.38 kb
XcmI fragment located 3 kb upstream of exon 1 to SpeI digested DNA. Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., and Pandolfi,
Rearrangement at the T cell receptor  locus was detected using a labeled P.P. (2001). Pten and p27KIP1 cooperate in prostate cancer tumor suppres-
1.6 kb BamHI/KpnI fragment located just 5 of C2 and hybridizing to BglII sion in the mouse. Nat. Genet. 27, 222–224.
digested DNA.
Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery,
C.A., Jr., Butel, J.S., and Bradley, A. (1992). Mice deficient for p53 areTUNEL staining
developmentally normal but susceptible to spontaneous tumours. NatureDetection of DNA strand breaks within apoptotic cells was carried out using
356, 215–221.the In Situ Cell Death Detection Kit (Catalog # 1 684 809, Roche Diagnostics,
Mannheim, Germany). Staining of 5M cryopreserved sections was per- Dunaief, J.L., Strober, B.E., Guha, S., Khavari, P.A., Alin, K., Luban, J.,
formed according to the manufacturer’s directions with the exception that Begemann, M., Crabtree, G.R., and Goff, S.P. (1994). The retinoblastoma
permeabilization was carried out for 10 min in 0.1% Triton X-100, 0.1% protein and BRG1 form a complex and cooperate to induce cell cycle arrest.
sodium citrate. Cell 79, 119–130.
Gnarra, J.R., Ward, J.M., Porter, F.D., Wagner, J.R., Devor, D.E., Grinberg,
Flow Cytometric Analysis A., Emmert-Buck, M.R., Westphal, H., Klausner, R.D., and Linehan, W.M.
Four-color immunostaining of primary thymocytes and splenocytes in single (1997). Defective placental vasculogenesis causes embryonic lethality in
cell suspension was carried out using the following antibodies: anti-CD4- VHL-deficient mice. Proc. Natl. Acad. Sci. USA 94, 9102–9107.
PE, anti-CD8-FITC, anti-TCR-APC, anti-B220-PerCP, anti-CD44-FITC,
Guidi, C.J., Sands, A.T., Zambrowicz, B.P., Turner, T.K., Demers, D.A., Web-anti-CD25-APC, anti-CD3-APC, anti-CD8-PerCP, anti-IgM-PE, and anti-
ster, W., Smith, T.W., Imbalzano, A.N., and Jones, S.N. (2001). DisruptionIgD-FITC (all antibodies obtained from BD PharMingen, San Diego, CA).
of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol.Analysis of V T cell receptor was carried out with 15 individual FITC-conju-
Cell. Biol. 21, 3598–3603.gated monoclonal antibodies that recognize V 2, 3, 4, 5.1 and 5.2, 6, 7,
8.1 and 8.2, 8.3, 9, 10b, 11, 12, 13, 14 and 17a T cell receptors (V TCR Hoffman, B., Amanullah, A., Shafarenko, M., and Liebermann, D.A. (2002).
Screening Panel, catalog #0143KK, BD PharMingen, San Diego, CA). The proto-oncogene c-myc in hematopoietic development and leukemogen-
Detection of apoptotic cells by flow cytometry was carried out with the esis. Oncogene 21, 3414–3421.
Anexin-V-FLUOS Staining Kit according to the manufacturer’s instructions
Hu, N., Gutsmann, A., Herbert, D.C., Bradley, A., Lee, W.H., and Lee, E.Y.(Catalog # 1 858 777, Roche Diagnostics, Mannheim, Germany).
(1994). Heterozygous Rb-1 delta 20/ mice are predisposed to tumors of the
pituitary gland with a nearly complete penetrance. Oncogene 9, 1021–1027.
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